Please login to the form below

Not currently logged in
Email:
Password:

GSK's Rotarix rotavirus vaccine wins FDA review

GSK wins FDA review for its Biologics License Application for Rotarix, an orally available candidate vaccine for infants to prevent rotavirus gastroenteritis

GlaxoSmithKline (GSK) has won FDA review for its Biologics License Application (BLA) for Rotarix, an orally available candidate vaccine for infants to prevent rotavirus gastroenteritis.

The BLA for the GSK rotavirus candidate vaccine is based on one of the largest clinical development plans undertaken by a vaccine manufacturer and includes data from nearly 75,000 infants. The clinical trials were conducted in the Americas, Europe, Asia and Africa and reflect an ethnically diverse population.

Rotavirus is the most common cause of hospitalisation due to severe dehydration caused by vomiting and diarrhoea in children worldwide according to the ESPID-ESPGHAN Rotavirus Expert Group.

Of children hospitalised with rotavirus, approximately 17 per cent are aged under six months old.  If approved, the GSK candidate vaccine would provide completion of the rotavirus vaccination series by four months. 

In the US, the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP) recommend that infants receive routine vaccination against rotavirus to prevent rotavirus gastroenteritis with the vaccine currently licensed by the FDA at two, four, and six months of age.

GSK's Rotarix vaccine is a live-attenuated vaccine derived from the most common human rotavirus strain. Published data show that immunity resulting from natural human rotavirus infection provides significant protection against moderate to severe disease, regardless of rotavirus strain.

Rotarix was first launched in Mexico in 2005 and has already been licensed in a total of 33 countries. GSK Bio submitted a registration file for Rotarix to the European Medicines Agency (EMEA) in December 2004.

By 2010, the potential market for rotavirus vaccines is estimated to be between GBP 1bn to GBP 1.3bn worldwide.

15th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics